Form 4: TriSalus Life Sciences Director Acquires Stock Options
SEC Form 4 Filing
Liselotte Hyveled, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.
Summary
- Liselotte Hyveled, a director at TriSalus Life Sciences, acquired stock options on August 13, 2024.
- The options grant the right to buy 15,000 shares of common stock at an exercise price of $5.75.
- The options vest fully on the one-year anniversary of the grant date or at the next annual stockholder meeting, contingent on continued service with the issuer.
- The options expire on August 12, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It indicates confidence but doesn't provide specific financial insights.
Positives
- The acquisition of stock options by a director signals confidence in the company's future prospects.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in corporate governance to align the interests of management and shareholders.
Stakeholder Impact
- The acquisition of stock options by a director can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date of the stock option transaction. |
| 08/13/2024 | Grant date of the stock options. |
| 08/13/2025 | Date the shares subject to the option shall fully vest. |
| 08/12/2034 | Expiration date of the stock options. |
| 08/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.